Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 11/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 11/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 11/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.90 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.90 |
| ▸ | ERN2 | Q76MJ5 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8186 SCHEMBL1638875 | 0.95 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Azd-8186 SCHEMBL1636956 | 0.95 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Azd-8186 SCHEMBL1638635 | 0.95 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12668363 | 0.91 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638117 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1637208 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638278 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638125 | 0.90 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638867 | 0.89 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638272 | 0.89 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-9718800-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2016-03-03 | — | — | US | disclosed |
| US-9029374-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA INTELLECTUAL PROPERTY (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA INTELLECTUAL PROPERTY (GB) | 2013-06-20 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CB 3920/4885PIK3CD 3037/4885PIK3CA 2099/4885 |
| US-20160272607-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CB 3920/4885PIK3CD 3037/4885PIK3CA 2099/4885 |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CB 3920/4885PIK3CD 3037/4885PIK3CA 2099/4885 |
| US-20160060240-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CB 3920/4885PIK3CD 3037/4885PIK3CA 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.